Expert Briefing: New Immunotherapy Technologies Provide Hope In Breast and how to get cialis no prescription Ovarian Cancer

Print E-mail
By M.E.Garza   
Wednesday, 23 July 2014 04:20

icon_expertbriefingLast month, TapImmune Inc. (OTCQB: TPIV) announced that Dr. Keith Knutson, PhD had been appointed to chair the cialis usa company’s scientific advisory board.

Read more...
 

Can Good News Flow Continue for CEL-SCI?

Print E-mail
By Peter Depalma   
Wednesday, 23 July 2014 02:54

icon_closerlookYesterday morning, CEL-SCI Corporation (NYSE MKT: CVM) announced that Turkey’s Ministry of Health had cleared the cialis delivered overnight company to begin patient enrollment in CEL-SCI’s global pivotal Phase III Head and cheap viagra without rx Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine.

Read more...
 

Sage Therapeutics: Hot IPO, Great Start in CNS

Print E-mail
By Brian Wilson   
Sunday, 20 July 2014 22:44

Last week, we saw a very successful IPO for Sage Therapeutics (SAGE) - a company that focuses on treating rare diseases that affect the where to buy cialis now central nervous system. Although the buying real viagra without prescription company is still in the cheapest cialis relatively early stages of the generic cialis cheap development cycle, the company has already attained an enterprise valuation of $696 M after investors brought the buy viagra without rx stock 67% higher last Friday. 

Read more...
 

Don’t Buy Into In Prana’s Data Mining Strategy

Print E-mail
By Brian Wilson   
Thursday, 17 July 2014 11:23

Despite the buying viagra with no prescription continuing pain in the biotech sector, Prana (PRAN) is up 15% at time of writing based on a press release issued yesterday about the cialis 50 mg company’s efforts to revive the canadian viagra and healthcare failed Alzheimer’s drug PBT2.

 

Read more...
 

Bigger Moves Coming For Exelixis

Print E-mail
By Brian Wilson   
Tuesday, 15 July 2014 08:05

It took a while for investor sentiment in Exelixis (EXEL) to recover after the company released less-than-stellar interim results for its Phase III Metastatic Castration-Resistant Prostate Cancer (mCRPC) trial for cabozantinib (COMET-1) back in March, but it appears that positive news from the cobimetinib program is helping to lighten the mood a bit.

Read more...
 

Q&A with Zami Aberman, Pluristem Therapeutics

Print E-mail
By BioMedReports.Com   
Monday, 14 July 2014 17:17
Zami Aberman, CEO of Haifa-based Pluristem Therapeutics, a leading developer of placenta-based cell therapies, recently announced the initiation of South Korean sites in the Phase II study assessing PLacental eXpanded (PLX) cells in the treatment of intermittent claudication (IC).
Read more...
 

Insiders Are Dumping Questcor – Here’s Why

Print E-mail
By Brian Wilson   
Monday, 14 July 2014 08:16

After a 70% rally since the start of the year, it’s time to reevaluate the valuation of Questcor Pharma (QCOR) and the reasoning behind the sale of ~1.3 million shares by insiders since January 1st.

Read more...
 

Investor Panic Sends Sarepta Down Sharply

Print E-mail
By Brian Wilson   
Thursday, 10 July 2014 09:12

Earlier this morning, Sarepta Therapeutics (NASDAQ: SRPT) announced long-term outcomes (through 144 weeks) from the Phase IIb study of the drug eteplirsen for Duchenne Muscular Dystrophy. This 12 patient trial, which was initiated in February 2012, has been the primary driver of Sarepta’s valuation for roughly three years.

Read more...
 

Will New Trials Renew Enthusiasm In La Jolla Pharma?

Print E-mail
By Brian Wilson   
Wednesday, 09 July 2014 07:44
La Jolla Pharma (LJPC) is a small pharmaceutical company that focuses on galectin inhibition, iron absorption deficiencies, and on hypotension. 

Read more...
 

Tekmira Selloff Could Be Exaggerated

Print E-mail
By Brian Wilson - Lead Contributor   
Monday, 07 July 2014 08:30

On July 3rd of last week, Tekmira (TKMR) fell over 15% after the FDA put a clinical hold on the company’s Phase I trial for TKM-Ebola – an early-stage RNAi therapeutic for the Ebola virus.

Read more...
 
<< Start < Prev 1 3 4 5 6 7 8 9 10 > End >>

Page 1 of 46
BioMedReports FDA Issued Form 483 with 10 Inspectional Observations for Impax Taiwan Plant; Pfenex Announces Closing of Init... http://t.co/o9bdAhSIEB
41mreplyretweetfavorite
BioMedReports Healthcare Review: Synthetic Biologics, Herbalife, Cynosure, Targacept, Galectin Therapeutics: U.S. stocks mos... http://t.co/RScEt1mmrk
4hreplyretweetfavorite
BioMedReports Cancer experts warn EU data law could 'halt' research... http://t.co/HRlTfbM3Mq
23hreplyretweetfavorite